Below you will find relevant news links and information:
MDCSCO Spring 2012 Newsletter (pdf)
Past Newsletter Issues:
MDCSCO Winter 2011 Newsletter (pdf)
MDCSCO Fall 2009 Newsletter (pdf)
MDCSCO Winter 2008 Newsletter (pdf)
**************************
News:
Mathias' cancer treatment bill gets unanimous OK
Written by Jennifer Shutt
ANNAPOLIS -- It's not every day a bill passes both houses of the Maryland General Assembly without one delegate or senator voting against it, but that's what happened Friday when the Kathleen Mathias Chemotherapy Parity Act of 2012 was voted on to the governor's desk. "We're elated and grateful for all the people who worked to make this happen," said Sen. Jim Mathias, D-38-Worcester. "People will be able to get the drugs they need. ... Kathy is still at work." The legislation will prohibit health insurers, nonprofit health service plans and health maintenance organizations that provide coverage for cancer chemotherapy from imposing limits or cost sharing on coverage for orally administered chemotherapy.
2011 Annual Report
Click the link above to see the 2011 Annual Report and Overview of MDCSCO
Insurance loophole on cancer treatments sticks patients with extreme cost
Nobody likes paying a lot for health insurance, but at least it provides peace of mind. Even while we grumble about steadily rising deductibles and co-pays, we figure if we get really sick — with cancer, say — then insurance will handle the bills.
Novartis Pharmaceuticals Corporation Announces Afinitor tablets
Novartis Pharmaceuticals Corporation is pleased to announce the introduction of Afinitor® (everolimus) tablets, approved by the FDA on March 30, 2009. Afinitor® is a once daily oral mTOR inhibitor indicated for the treatment of advanced Renal Cell Carcinoma (RCC). Afinitor® is available by prescription only and package in a blister card. Click here for more information.
Velcade- Highlights of Prescribing Information
Velcade Physician Announcement Letter
Velcade Press Release
FDA APPROVES ADDITION OF SUSTAINED OVERALL SURVIVAL BENEFIT TO LABEL FOR VELCADE® (BORTEZOMIB) FOR INJECTION FOR PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
|
